Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

被引：12
|
作者：
Allan, John N.
Shanafelt, Tait
Wiestner, Adrian
Moreno, Carol
O'Brien, Susan M.
Braggio, Esteban
Liu, Emily
Dean, James P.
Lai, Dominic
Ahn, Inhye E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134431
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials
    Allan, John N.
    Shanafelt, Tait
    Wiestner, Adrian
    Moreno, Carol
    O'Brien, Susan M.
    Li, Jianling
    Krigsfeld, Gabriel
    Dean, James P.
    Ahn, Inhye E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) : 947 - 953
  • [2] 17P deletion and TP53 gene mutation (17P/TP53) testing behaviour and treatment patterns for chronic lymphocytic leukemia (CLL) patients in France, Germany, Italy, Spain and UK (EU5)
    Canta, F. A. Bermudez
    Mitrofan, L.
    Karanis, Y. B.
    Mistry, H.
    Anger, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] No benefit from adding rituximab to ibrutinib in relapsed or refractory chronic lymphocytic leukemia or 17p deletion/TP53 mutation
    Calleja, Anne
    HEMATOLOGIE, 2019, 25 (03): : 131 - 132
  • [4] Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
    Jain, Nitin
    Thompson, Philip A.
    Burger, Jan A.
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Estrov, Zeev E.
    Borthakur, Gautam M.
    Bose, Prithviraj
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Sasaki, Koji
    Garg, Naveen
    Wang, Xuemei
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Lopez, Wanda
    Ayala, Ana
    Plunkett, William
    Gandhi, Varsha
    Kantarjian, Hagop M.
    O'Brien, Susan
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2019, 134
  • [5] Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
    Yuan Hong
    Xichuang Chen
    Yuanquan Hong
    Xingfang Xiao
    Yan Wang
    Xiaohong You
    Jingyi Mi
    Tao Zhou
    Panpan Zheng
    Zhihu Huang
    BMC Health Services Research, 23
  • [6] Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study
    Hong, Yuan
    Chen, Xichuang
    Hong, Yuanquan
    Xiao, Xingfang
    Wang, Yan
    You, Xiaohong
    Mi, Jingyi
    Zhou, Tao
    Zheng, Panpan
    Huang, Zhihu
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [7] Prognostic Impact of TP53 Mutation in Combination with Chromosome 17p Deletion in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Yun, Seongseok
    Sandoval-Sus, Jose
    Knepper, Todd C.
    Teer, Jamie
    Chavez, Julio C.
    Pinilla-Ibarz, Javier
    BLOOD, 2017, 130
  • [8] Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab ( iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses
    Jain, Nitin
    Thompson, Philip
    Jain, Akhil
    Burger, Jan A.
    Ferrajoli, Alessandra
    Senapati, Jayastu
    Takahashi, Koichi
    Swaminathan, Mahesh
    Estrov, Zeev
    Borthakur, Gautam
    Bose, Prithviraj
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Sasaki, Koji
    Bansal, Divyam
    Konopleva, Marina Y.
    Jabbour, Elias
    Garg, Naveen
    Wang, Xuemei
    Kanagal-Shamanna, Rashmi
    Patel, Keyur P.
    Wang, Wei
    Wang, Sa A.
    Jorgensen, Jeffrey L.
    Lopez, Wanda
    Ayala, Ana
    Plunkett, William
    Gandhi, Varsha
    Kantarjian, Hagop M.
    O'Brien, Susan M.
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2023, 142
  • [9] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION
    Pileckyte, R.
    Valceckiene, V.
    Zvirblis, T.
    Griskevicius, L.
    HAEMATOLOGICA, 2012, 97 : 525 - 526
  • [10] Treatment Outcomes Among Chronic Lymphocytic Leukemia Patients with 17p Deletion or TP53 Mutation in Argentina: A Retrospective Chart Review
    Pavlovsky, Miguel A.
    Sail, Kavita
    Chaves, Leonardo Passos
    Kamalakar, Rajesh
    Ma, Xiaojing
    Brandalise, Patricia
    Chiattone, Carlos
    BLOOD, 2017, 130
12345